Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer
Recruiting · NCT07021911 · Observational (researchers observe without assigning treatment)
View the official record on ClinicalTrials.gov →Interventions studied
Radiotherapy
What this trial is about
The primary objective of the study is to describe the tolerance profile of radiation treatments performed during systemic treatment with new drugs (molecular targeted therapies, immunotherapy, others).
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients suffering from stage IV breast cancer
- Ongoing systemic treatment including: molecular targeted therapy, conjugated antibodies, monoclonal antibodies, tyrosine kinase inhibitors, immunotherapy (immunocheckpoint inhibitors)
- Candidates for radiation treatment (both palliative and curative).
Exclusion criteria
- Previous radiation treatment on the same site
- Absolute contraindications to radiotherapy
- Systemic treatment administered as part of a clinical trial
Where it is running
1 location listed.
- Radiation Oncology Department Fondazione Policlinico Campus BioMedico - Rome, Italy, Italy